280E Updates: Rescheduling, Amending Returns, and Why Timing Matters - Sign up for our free webinar now!

280E Updates: Rescheduling, Amending Returns, and Why Timing Matters - Sign up for our free webinar now!

Cannabis 2017 Highlights and A Look Toward This Year's Conference | Cannabis Business Times

Sign in or create a free Cannabis Business Times account to continue reading

Continue to Site »
Site will load in 15 seconds

Continue to Site »X

Cannabis 2017 Highlights and A Look Toward This Year's Conference

We look back at last year's Cannabis 2017 Cultivation Conference in Oakland, Calif. Join us this year! Visit cannabiscultivationconference.com for more information.

February 5, 2018

8th Annual ‘Best Cannabis Companies to Work For’ Now Open for Entries

PleoPharma Announces 1st Patient Dosed in Phase 3 Clinical Trial for Cannabis Use Disorder

Best Cannabis Companies to Work For

How to Turn LED Lighting Into a Strategic Cultivation Tool

Sens. Ted Budd and Pete Ricketts' Hemp Product Ban Amendment

NMAI Letter RE: Final Determination Regarding Idaho Medical Cannabis Act Initiative Petition

What Is Certified Human-Composed Creation and Why Is It Important?

Massachusetts State Ballot Law Commission Ruling on Cannabis Petition - July 21, 2026

NDASA and MMJ Response to DOJ's Schedule III Stay Opposition - July 16, 2026

Image Distillate

Image Trimmer Test

Massachusetts State Ballot Law Commission Notice of Hearing 26-06 - July 2026

Kevin Gilnack Objection to Massachusetts Cannabis Petition Filed With State Ballot Law Commission -- July 8, 2026

Massachusetts Elections Division Letter to Coalition for a Healthy Massachusetts - July 9, 2026

DOJ Response Opposing NDASA/MMJ's Motion to Stay Schedule III Order

PleoPharma Announces 1st Patient Dosed in Phase 3 Clinical Trial for Cannabis Use Disorder

The trial of PP-01 (CAN-004) advances an investigational, once-daily therapy for withdrawal symptoms in patients with cannabis use disorder.

Page 1 of 10